| Long name: |
DPYD Primary Polyclonal Antibody |
| Also known as: |
DPYD PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
DPYD |
| Specificity: |
This is a highly specific antibody against DPYD |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human DPYD |
| Gene ID number: |
1806 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs, DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU, DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU, Leukopenia, Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil, Specifically, This reaction includes stomatitis, Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene, a deficiency of DPYD leads to an accumulation of uracil and thymine, also known as hereditary thymine-uraciluria or familial pyrimidinemia, and neurologic symptoms, cerebellar ataxia, diarrhea, fever, hair loss, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression, marked weight loss, progressing to semicoma, thrombocytopenia, thus, thymine and 5-hydroxymethyluracil, Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
DHPDHase, DPD, DPYD, DPYD_HUMAN, Dihydropyrimidine dehydrogenase, Dihydropyrimidine dehydrogenase [NADP+], Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, MGC132008, MGC70799, OTTHUMP00000058954, DHP |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
DPYD |
| Short name: |
DPYD Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
DPYD (Antibody to) |
| Alternative technique: |
antibodies |
| Identity: |
3012 |
| Gene: |
DPYD |
More about : DPYD |
| Long gene name: |
dihydropyrimidine dehydrogenase |
| Synonyms: |
DPD |
| Locus: |
1p21, 3 |
| Discovery year: |
1994-07-07 |
| GenBank acession: |
U20938 |
| Entrez gene record: |
1806 |
| Pubmed identfication: |
7713523 |
| RefSeq identity: |
NM_000110 |
| Havana BLAST/BLAT: |
OTTHUMG00000039683 |
| Locus Specific Databases: |
UMD Locus Specific Databases LRG_722 |